U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Morbidity and Mortality Weekly Report (MMWR)

CDC Stacks Public Health Publications

The Morbidity and Mortality Weekly Report (MMWR) series are CDC’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. The MMWR series includes the following publications: MMWR Weekly, MMWR Recommendations and Reports, CDC Surveillance Summaries and MMWR Supplements. These journals are freely available to the public as Diamond Open Access. For more on MMWR, visit https://www.cdc.gov/mmwr/index.html.

(45)
(67)
(184)
(229)
(500)
(673)
(659)
(403)
(489)
(557)
(246)
(325)
(427)
(406)
(97)
(156)
(103)
(110)
(97)
(92)
(119)
(92)
(108)
(96)
(97)
(92)
(79)
(97)
(87)
(91)
(88)
(76)
(74)
(84)
(80)
(69)
(70)
(73)
(68)
(69)
(59)
(67)
(62)
(64)
(62)
(66)
(72)
(55)
(53)
(55)
(60)
(56)
(58)
(54)
(53)
(56)
(55)
(52)
(54)
(53)
(54)
(54)
(53)
(53)
(53)
(53)
(54)
(53)
(53)
(53)
(53)
(54)
(53)
(53)
(51)
0 of 75
(44)
(63)
(187)
(222)
(500)
(663)
(656)
(409)
(483)
(558)
(231)
(311)
(436)
(413)
(91)
(148)
(100)
(104)
(102)
(92)
(120)
(92)
(104)
(97)
(97)
(91)
(80)
(97)
(86)
(90)
(87)
(76)
(75)
(84)
(80)
(69)
(69)
(71)
(69)
(64)
(60)
(68)
(62)
(62)
(62)
(67)
(72)
(56)
(55)
(54)
(59)
(57)
(58)
(54)
(53)
(55)
(55)
(55)
(53)
(53)
(53)
(53)
(54)
(53)
(53)
(53)
(53)
(53)
(54)
(54)
(53)
(53)
(53)
(53)
(54)
0 of 75
(1)
(7)
(33)
(71)
(44)
(137)
(157)
(161)
(151)
(137)
(163)
(169)
(155)
(160)
(161)
(157)
(163)
(164)
(156)
(164)
(156)
(173)
(142)
(155)
(159)
(134)
(156)
(141)
(142)
(141)
(137)
(138)
(142)
(131)
(162)
(144)
(136)
(152)
(152)
(177)
(206)
(197)
(164)
(187)
(179)
(201)
(205)
(202)
(223)
(225)
(232)
(221)
(225)
(252)
(252)
(277)
0 of 56
(2)
(1)
(4)
(1)
(431)
(107)
(405)
(13)
(8547)
0 of 9
(16)
(34)
(37)
(4)
(1)
(2)
(6)
(1)
0 of 8
(10)
(10)
(25)
(11)
(7)
(20)
(27)
(42)
(58)
(7)
(23)
(13)
(7)
(38)
(10)
(10)
(50)
(7)
(33)
(1236)
(23)
(1293)
(32)
(71)
(10)
(91)
(26)
(16)
(7)
(791)
(198)
(24)
(128)
(70)
(39)
(61)
(10)
(9)
(11)
(17)
(20)
(38)
(19)
(26)
(15)
(26)
(9)
(11)
(17)
(10)
(7)
(48)
(11)
(8)
(223)
(17)
(17)
(8)
(181)
(137)
(129)
(32)
(8)
(15)
(13)
(9)
(10)
(13)
(15)
(9)
(15)
(8)
(29)
(17)
(10)
(7)
(18)
(100)
(13)
(12)
(36)
(18)
(8)
(12)
(7)
(11)
(11)
(30)
(9)
(9)
(9)
(15)
(21)
(8)
(17)
(7)
(8)
(31)
(77)
(10)
(61)
(7)
(7)
(14)
(12)
(13)
(15)
(19)
(85)
(13)
(11)
(14)
(31)
(14)
(13)
(30)
(28)
(12)
(187)
(7)
(7)
(17)
(8)
(18)
(53)
(11)
(7)
(17)
(22)
(20)
(7)
(15)
(10)
(9)
(24)
(13)
(31)
(20)
(29)
(7)
(13)
(13)
(31)
(73)
(10)
(21)
(24)
(8)
(26)
(20)
(7)
(7)
(8)
(13)
(28)
(25)
(9)
(940)
(740)
(9)
(14)
(7)
(14)
(35)
(7)
(103)
(10)
(51)
(10)
(19)
(11)
(11)
(9)
(58)
(12)
(20)
(14)
(49)
(20)
(21)
(19)
(20)
(16)
(177)
(80)
(2979)
(37)
(12)
(546)
(316)
(260)
(215)
(24)
(38)
(14)
(15)
(14)
(12)
(34)
(10)
(80)
(14)
(11)
(8)
(23)
(8)
(8)
(28)
(446)
(21)
(23)
(15)
(8)
(74)
(25)
(19)
(9)
(18)
(18)
(18)
(45)
(687)
(8)
(10)
(15)
(59)
(205)
(7)
(10)
(18)
(8)
(12)
(66)
(24)
(14)
(40)
(73)
(8)
(11)
(8)
(11)
(20)
(19)
(23)
(58)
(9)
(8)
(16)
(33)
(44)
(82)
(9)
(10)
(8)
(21)
(65)
(8)
(13)
(14)
(28)
(25)
(14)
(10)
(10)
(8)
(166)
(24)
(14)
(35)
(26)
(9)
(11)
(9)
(24)
(26)
(12)
(92)
(4170)
(636)
(34)
(12)
(17)
(10)
(14)
(11)
(12)
(13)
(9)
(28)
(16)
(19)
(8)
(8)
(12)
(27)
(17)
(14)
(44)
(20)
(28)
(36)
(10)
(20)
(8)
(21)
(8)
(66)
(91)
(24)
(9)
(27)
(13)
(21)
(22)
(8)
(39)
(56)
(68)
(21)
(15)
(149)
(8)
(12)
(32)
(16)
(14)
(19)
(19)
(16)
(22)
(10)
(11)
(144)
(45)
(32)
(9)
(41)
(32)
(15)
(654)
(51)
(26)
(9)
(56)
(14)
(130)
(9)
(18)
(62)
(8)
(10)
(10)
(30)
(11)
(10)
(13)
(21)
(8)
(15)
(23)
(111)
(23)
(1338)
(14)
(10)
(17)
(11)
(13)
(8)
(8)
(48)
(8)
(25)
(186)
(14)
(42)
(45)
(25)
(47)
(13)
(16)
(11)
(593)
(394)
(15)
(21)
(14)
(152)
(15)
(53)
(9)
(28)
(10)
(19)
(11)
(8)
(8)
(110)
(10)
(78)
(11)
(52)
(68)
(59)
(17)
(23)
(60)
(132)
(19)
(105)
(58)
(12)
(39)
(126)
(35)
(97)
(17)
(10)
(11)
(12)
(12)
(8)
(14)
(52)
(69)
(116)
(29)
(172)
(25)
(17)
(50)
(12)
(10)
(33)
(12)
(10)
(45)
(11)
(8)
(8)
(60)
(31)
(90)
(44)
(19)
(159)
(10)
(14)
(31)
(8)
(8)
(9)
(9)
(12)
(28)
(51)
(9)
(206)
(18)
(31)
(17)
(19)
(2445)
(16)
(18)
(18)
(11)
(104)
(20)
(38)
(8)
(206)
(231)
(23)
(8)
(8)
(9)
(18)
(240)
(11)
(49)
(678)
(10)
(307)
(15)
(47)
(61)
(23)
(17)
(8)
(21)
(595)
(13)
(61)
(15)
(14)
(9)
(37)
(26)
(22)
(29)
(188)
(45)
(54)
(48)
(8)
(114)
(50)
(10)
(125)
(28)
(11)
(12)
(8)
(32)
(22)
(8)
(12)
(8)
(22)
(13)
(61)
(16)
(11)
(10)
(73)
(9)
(10)
(10)
(74)
(32)
(114)
(9)
(13)
(41)
(17)
(55)
(17)
(13)
(16)
(18)
(10)
(17)
(44)
(66)
(10)
(11)
(9)
(10)
(177)
(17)
(12)
(14)
(1181)
(9)
(9)
(8)
(50)
(10)
(44)
(109)
(10)
(16)
(8)
(19)
(308)
(40)
(33)
(23)
(11)
(12)
(9)
(83)
(11)
(12)
(18)
(20)
(8)
(11)
(8)
(8)
(19)
(58)
(32)
(82)
(14)
(37)
(8)
(21)
(40)
(13)
(17)
(17)
(9)
(9)
(66)
(19)
(963)
(103)
(15)
(48)
(30)
(12)
(8)
(10)
(57)
(3831)
(11)
(9)
(9)
(31)
(16)
(21)
(16)
(16)
(15)
(17)
(10)
(13)
(8)
(8)
(11)
(18)
(9)
(14)
(15)
(9)
(16)
(41)
(43)
(20)
(10)
(27)
(11)
(12)
(10)
(15)
(243)
(18)
(22)
(8)
(36)
(14)
(113)
(10)
(257)
(611)
(72)
(11)
(21)
(17)
(8)
(11)
(15)
(9)
(10)
(299)
(12)
(10)
(8)
(14)
(11)
(12)
(11)
(20)
(10)
(10)
(16)
(13)
(13)
(10)
(22)
(10)
(65)
(10)
(9)
(10)
(9)
(9)
(19)
(12)
(9)
(144)
(18)
(14)
(8)
(33)
(144)
(11)
(171)
(10)
(8)
(8)
(22)
(70)
(343)
(114)
(84)
(24)
(36)
(34)
(11)
(30)
(14)
(8)
(10)
(25)
(21)
(29)
(21)
(18)
(16)
(1141)
(18)
(27)
(18)
(22)
(110)
(15)
(22)
(23)
(349)
(10)
(18)
(72)
(16)
(15)
(26)
(14)
(27)
(35)
(10)
(9)
(11)
(216)
(50)
(16)
(23)
(34)
(21)
(10)
(19)
(74)
(20)
(9)
(233)
(1003)
(22)
(24)
(71)
(101)
(2518)
(11)
(104)
(12)
(23)
(15)
(16)
(14)
(93)
(177)
(38)
(279)
(15)
(8)
(9)
(13)
(45)
(32)
(91)
(9)
(17)
(18)
(16)
(23)
(71)
(37)
(18)
(12)
(8)
(12)
(21)
(10)
(28)
(10)
(10)
(8)
(24)
(104)
(187)
(28)
(29)
(25)
(10)
(20)
(9)
(58)
(67)
(195)
(303)
(8)
(14)
(11)
(21)
(12)
(8)
(58)
(17)
(34)
(9)
(38)
(617)
(31)
(32)
(146)
(241)
(12)
(177)
(10)
(18)
(10)
(122)
(8)
(11)
(126)
(9)
(16)
(18)
(15)
(20)
(11)
(9)
(19)
(11)
(28)
(35)
(38)
(11)
(8)
(65)
(22)
(16)
(40)
(28)
(10)
(14)
(10)
(14)
(12)
(80)
(31)
(8)
(39)
(9)
(20)
(18)
(12)
(184)
(9)
(28)
(23)
(70)
(25)
(23)
(25)
(14)
(8)
(9)
(108)
(8)
(22)
(16)
(44)
(16)
(134)
(51)
(10)
(19)
(10)
(56)
(9)
(8)
(12)
(18)
(94)
(35)
(31)
(12)
(49)
(8)
(38)
(91)
(9)
(22)
(14)
(182)
(10)
(8)
(8)
(19)
(33)
(21)
(19)
(12)
(8)
(69)
(9)
(8)
(54)
(15)
(12)
(8)
(15)
(8)
(10)
(58)
(19)
(181)
(28)
(36)
(22)
(106)
(19)
(157)
(13)
(9)
(12)
(15)
(68)
(9)
(14)
(182)
(10)
(10)
(19)
(70)
(18)
(29)
(17)
(50)
(17)
(19)
(9)
(14)
(464)
(11)
(48)
(49)
(104)
(17)
(102)
(29)
(25)
(34)
(21)
(40)
(8)
(10)
(23)
(31)
(20)
(35)
(21)
(12)
(18)
(8)
(43)
(94)
(22)
(26)
(9)
(23)
(9)
(12)
(8)
(39)
(14)
(14)
(59)
(11)
(9)
(38)
(17)
(16)
(39)
(15)
(78)
(8)
(10)
(43)
(13)
(15)
(46)
(27)
(763)
(30)
(57)
(10)
(12)
(29)
0 of 1000
(12)
(12)
(15)
(7)
(23)
(9)
(7)
(18)
(8)
(7)
(10)
(11)
(7)
(9)
(7)
(10)
(9)
(11)
(11)
(19)
(9)
(11)
(9)
(10)
(27)
(8)
(9)
(12)
(23)
(15)
(9)
(7)
(7)
(7)
(9)
(13)
(11)
(9)
(15)
(7)
(7)
(7)
(7)
(9)
(8)
(19)
(9)
(9)
(7)
(7)
(13)
(7)
(7)
(9)
(7)
(9)
(7)
(16)
(13)
(7)
(12)
(12)
(22)
(28)
(15)
(8)
(8)
(13)
(7)
(19)
(12)
(12)
(13)
(15)
(16)
(9)
(10)
(7)
(11)
(28)
(7)
(13)
(28)
(7)
(10)
(11)
(11)
(13)
(10)
(8)
(18)
(9)
(10)
(16)
(29)
(8)
(12)
(12)
(13)
(8)
(9)
(7)
(28)
(9)
(16)
(7)
(29)
(7)
(8)
(8)
(11)
(16)
(16)
(12)
(35)
(8)
(11)
(16)
(18)
(9)
(29)
(9)
(14)
(22)
(31)
(11)
(7)
(7)
(10)
(7)
(18)
(9)
(7)
(9)
(7)
(7)
(7)
(11)
(9)
(23)
(20)
(10)
(7)
(7)
(15)
(10)
(8)
(37)
(8)
(22)
(10)
(16)
(11)
(10)
(24)
(13)
(7)
(11)
(7)
(9)
(11)
(9)
(12)
(21)
(9)
(9)
(7)
(11)
(7)
(16)
(9)
(7)
(9)
(12)
(19)
(12)
(7)
(7)
(7)
(11)
(10)
(7)
(9)
(24)
(7)
(8)
(10)
(12)
(8)
(13)
(25)
(23)
(7)
(24)
(16)
(9)
(7)
(10)
(9)
(8)
(8)
(13)
(9)
(9)
(10)
(7)
(10)
(7)
(20)
(8)
(9)
(7)
(18)
(17)
(11)
(10)
(12)
(9)
(12)
(7)
(9)
(7)
(9)
(8)
(15)
(8)
(8)
(13)
(28)
(7)
(18)
(8)
(12)
(15)
(7)
(7)
(17)
(17)
(8)
(16)
(8)
(20)
(7)
(8)
(11)
(11)
(21)
(8)
(11)
(10)
(13)
(9)
(8)
(7)
(12)
(8)
(15)
(9)
(11)
(7)
(17)
(12)
(17)
(16)
(7)
(18)
(24)
(11)
(7)
(7)
(12)
(8)
(19)
(20)
(16)
(11)
(12)
(7)
(8)
(10)
(14)
(16)
(7)
(9)
(11)
(20)
(15)
(9)
(16)
(48)
(9)
(11)
(24)
(11)
(8)
(9)
(7)
(10)
(9)
(7)
(10)
(8)
(53)
(13)
(9)
(11)
(15)
(42)
(16)
(8)
(8)
(29)
(10)
(7)
(10)
(8)
(8)
(24)
(8)
(11)
(12)
(8)
(13)
(21)
(24)
(10)
(10)
(16)
(20)
(11)
(10)
(15)
(17)
(12)
(18)
(7)
(17)
(16)
(10)
(15)
(18)
(14)
(16)
(22)
(7)
(9)
(17)
(12)
(15)
(8)
(18)
(20)
(15)
(11)
(29)
(7)
(10)
(23)
(7)
(7)
(27)
(8)
(7)
(26)
(18)
(8)
(12)
(11)
(8)
(36)
(15)
(12)
(7)
(8)
(15)
(16)
(7)
(7)
(9)
(10)
(9)
(17)
(7)
(12)
(12)
(13)
(12)
(16)
(9)
(13)
(8)
(15)
(24)
(8)
(8)
(8)
(7)
(17)
(9)
(7)
(28)
(12)
(15)
(13)
(9)
(7)
(7)
(9)
(8)
(7)
(8)
(14)
(9)
(14)
(17)
(7)
(8)
(7)
(10)
(11)
(7)
(16)
(9)
(59)
(12)
(8)
(8)
(7)
(7)
(9)
(7)
(18)
(7)
(8)
(18)
(9)
(15)
(10)
(8)
(25)
(11)
(8)
(9)
(14)
(26)
(23)
(8)
(43)
(11)
(14)
(7)
(15)
(11)
(20)
(7)
(28)
(15)
(10)
(9)
(25)
(18)
(7)
(8)
(8)
(7)
(18)
(15)
(15)
(11)
(7)
(8)
(7)
(10)
(14)
(8)
(30)
(15)
(7)
(9)
(19)
(18)
(15)
(9)
(7)
(7)
(8)
(13)
(11)
(15)
(17)
(8)
(49)
(7)
(32)
(13)
(10)
(16)
(7)
(23)
(24)
(9)
(10)
(25)
(8)
(20)
(7)
(7)
(13)
(7)
(11)
(9)
(7)
(7)
(10)
(9)
(8)
(9)
(7)
(7)
(10)
(16)
(14)
(12)
(7)
(10)
(20)
(9)
(15)
(7)
(7)
(11)
(12)
(11)
(13)
(8)
(7)
(19)
(26)
(17)
(7)
(15)
(9)
(8)
(18)
(17)
(8)
(8)
(12)
(7)
(10)
(7)
(9)
(8)
(18)
(18)
(11)
(8)
(35)
(21)
(7)
(7)
(18)
(9)
(7)
(10)
(7)
(10)
(9)
(14)
(14)
(10)
(24)
(12)
(8)
(53)
(7)
(7)
(7)
(19)
(8)
(10)
(10)
(8)
(10)
(7)
(9)
(8)
(8)
(20)
(13)
(27)
(8)
(8)
(19)
(7)
(19)
(7)
(11)
(7)
(12)
(7)
(11)
(11)
(28)
(10)
(9)
(7)
(20)
(10)
(13)
(7)
(8)
(9)
(13)
(11)
(10)
(7)
(13)
(9)
(7)
(10)
(8)
(7)
(7)
(10)
(14)
(9)
(38)
(23)
(10)
(8)
(7)
(10)
(11)
(10)
(13)
(15)
(10)
(7)
(17)
(10)
(7)
(7)
(11)
(11)
(12)
(8)
(10)
(18)
(14)
(8)
(10)
(21)
(16)
(14)
(14)
(9)
(15)
(9)
(19)
(24)
(11)
(20)
(21)
(16)
(7)
(7)
(10)
(23)
(7)
(8)
(17)
(7)
(9)
(10)
(7)
(7)
(17)
(8)
(8)
(7)
(9)
(9)
(13)
(10)
(8)
(13)
(9)
(13)
(8)
(18)
(7)
(7)
(27)
(12)
(8)
(15)
(9)
(17)
(8)
(18)
(7)
(26)
(12)
(9)
(11)
(22)
(7)
(10)
(7)
(7)
(13)
(7)
(7)
(8)
(10)
(21)
(15)
(14)
(35)
(18)
(7)
(7)
(7)
(8)
(21)
(16)
(24)
(24)
(18)
(8)
(7)
(18)
(12)
(7)
(7)
(13)
(25)
(7)
(8)
(12)
(11)
(19)
(7)
(27)
(18)
(10)
(10)
(8)
(12)
(7)
(7)
(7)
(10)
(7)
(7)
(10)
(16)
(12)
(10)
(7)
(18)
(7)
(25)
(10)
(15)
(10)
(18)
(24)
(13)
(16)
(9)
(19)
(13)
(26)
(16)
(18)
(8)
(10)
(8)
(10)
(14)
(7)
(10)
(7)
(13)
(7)
(7)
(11)
(17)
(15)
(13)
(13)
(13)
(8)
(33)
(8)
(11)
(11)
(8)
(11)
(12)
(21)
(10)
(9)
(12)
(23)
(8)
(11)
(14)
(8)
(19)
(11)
(8)
(8)
(11)
(9)
(8)
(11)
(10)
(8)
(8)
(14)
(13)
(10)
(16)
(9)
(30)
(11)
(11)
(10)
(14)
(23)
(8)
(9)
(12)
(11)
(10)
(8)
(8)
(9)
(20)
(17)
(12)
(10)
(8)
(18)
(13)
(17)
(11)
(9)
(29)
(10)
(9)
(13)
(11)
(8)
(29)
(13)
(13)
(9)
(11)
(40)
(8)
(10)
(12)
(14)
(8)
(13)
(16)
(9)
(12)
(8)
(9)
(11)
(8)
(9)
(40)
(10)
(9)
(20)
(17)
(8)
(24)
(13)
(10)
(24)
(9)
(18)
(20)
(9)
(9)
(8)
(8)
(29)
(15)
(8)
(73)
(9)
(38)
(8)
(23)
(10)
(24)
(9)
(12)
(9)
(8)
(10)
(12)
(11)
(8)
(22)
(9)
(13)
(10)
(16)
(8)
(9)
(13)
(17)
(11)
(8)
(12)
(15)
(9)
(9)
(13)
(9)
(8)
(20)
(14)
(32)
(9)
(16)
(10)
(10)
(10)
(12)
(8)
(9)
(33)
(16)
(8)
(10)
(8)
(11)
(13)
(14)
(21)
(10)
(15)
(8)
(8)
(12)
(8)
(15)
(12)
(18)
(9)
(12)
(13)
(13)
(23)
(11)
(15)
(11)
(9)
(8)
(8)
(13)
(25)
(13)
(17)
(8)
(13)
(11)
(13)
(11)
(9)
(10)
(8)
(10)
(21)
(13)
(21)
(23)
(25)
(8)
(9)
(11)
(11)
(15)
(10)
(13)
(10)
(9)
(19)
(14)
(10)
0 of 1000
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(5)
(4)
(1)
(1)
(1)
(1)
(3)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(3)
(1)
(3)
(1)
(2)
(1)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(7)
(3)
(2)
(3)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(8)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(13)
(1)
(1)
(7)
(1)
(16)
(14)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(33)
(1)
(2)
(106)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(4)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(6)
(1)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(3)
(1)
(1)
(2)
(68)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(8)
(4)
(1)
(3)
(6)
(5)
(2)
(1)
(11)
(1)
(2)
(3)
(1)
(7)
(1)
(4)
(1)
(1)
(1)
(3)
(1)
(6)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(12)
(1)
(3)
(1)
(1)
(3)
(1)
(1)
(116)
(1)
(2)
(1)
(1)
(4)
(22)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3941)
(6)
(1)
(1)
(2)
(11)
(10)
(1)
(1)
(41)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(14)
(1)
(1)
(1)
(4)
(20)
(1)
(7)
(3)
(1)
(1)
(1)
(3)
(1)
(1)
(5)
(1)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(3)
(13)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(7)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(65)
(3)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(3)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(33)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(21)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(3)
(3)
(1)
(1)
(1)
(1)
(425)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(1)
(6)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(13)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(3)
(2)
(2)
(2)
(4)
(3)
(3)
(4)
(2)
(5)
(1)
(2)
(3)
(2)
(3)
(9)
(2)
(2)
(2)
(2)
(9)
(2)
(7)
(4)
(2)
(2)
(5)
(2)
(12)
(12)
(2)
(7)
(4)
(2)
(3)
(2)
(3)
(4)
(4)
(2)
(5)
(7)
(4)
(2)
(5)
(7)
(2)
(9)
(2)
(2)
(8)
(2)
(2)
(2)
(4)
(9)
(3)
(3)
(2)
(2)
(5)
(9)
(4)
(4)
(2)
(2)
(5)
(4)
(2)
(3)
(3)
(9)
(4)
(4)
(6)
(4)
(2)
(3)
(2)
(6)
(2)
(11)
(2)
(3)
(2)
(2)
(2)
(3)
(10)
(4)
(2)
(8)
(2)
(15)
(2)
(2)
(20)
(2)
(3)
(6)
(2)
(2)
(5)
(2)
(13)
(11)
(2)
(24)
(2)
(3)
(3)
(7)
(2)
(3)
(3)
(3)
(2)
(9)
(2)
(14)
(2)
(7)
(3)
(4)
(3)
(2)
(3)
(9)
(5)
(9)
(50)
(8)
(3)
(13)
(3)
(3)
(2)
(4)
(3)
(9)
(5)
(3)
(2)
(2)
(2)
(15)
(9)
(5)
(4)
(2)
(5)
(4)
(5)
(4)
(5)
(5)
(11)
(4)
(12)
(5)
(2)
(2)
(7)
(5)
(3)
(2)
(5)
(2)
(2)
(3)
(2)
(3)
(2)
(2)
(149)
(7)
(2)
(2)
(3)
(3)
(3)
(3)
(2)
(6)
(2)
(3)
(3)
(10)
(2)
(16)
(2)
(7)
(9)
(6)
(4)
(7)
(5)
(4)
(11)
(3)
(4)
(13)
(17)
(2)
(24)
(2)
(2)
(4)
(8)
(7)
(11)
(8)
(5)
(3)
(13)
(4)
(17)
(6)
(9)
(2)
(22)
(2)
(2)
(6)
(3)
(9)
(3)
(2)
(4)
(15)
(3)
(4)
(3)
(8)
(15)
(6)
(2)
(23)
(2)
(2)
(4)
(5)
(5)
(24)
(2)
(4)
(2)
(7)
(2)
(2)
(9)
(3)
(2)
(9)
(6)
(11)
(5)
(15)
(4)
(2)
(3)
(5)
(6)
(2)
(118)
(5)
(18)
(3)
(2)
(7)
(125)
(2)
(3)
(2)
(5)
(7)
(2)
(3)
(2)
(4)
(6)
(6)
(3)
(3)
(2)
(3)
(2)
(10)
(12)
(4)
(2)
(3)
(3)
(4)
(9)
(2)
(2)
(2)
(5)
(6)
(4)
(2)
(2)
(13)
(2)
(4)
(2)
(2)
(2)
(4)
(3)
(9)
(2)
(4)
(2)
(2)
(2)
(7)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(4)
(3)
(3)
(3)
(4)
(12)
(4)
(2)
(5)
(6)
(5)
(2)
(3)
(14)
(4)
(2)
(2)
(2)
(2)
(2)
(14)
(7)
(7)
(3)
(2)
(3)
(2)
(2)
(2)
(44)
(183)
(2)
(88)
(115)
(2)
(8)
(16)
(10)
(5)
(2)
(14)
(180)
(2)
(3)
(3)
(6)
(93)
(2)
(2)
(2)
(4)
(317)
(7)
(11)
(2)
(6)
(8)
(2)
(3)
(26)
(80)
(2)
(2)
(22)
(3)
(2)
(36)
(30)
(10)
(4)
(3)
(6)
(2)
(3)
(4)
(3)
(2)
(4)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(2)
(2)
(4)
(2)
(2)
(4)
(2)
(3)
(2)
(2)
(2)
(2)
(4)
(3)
(2)
(5)
(2)
(2)
(4)
(2)
(2)
(2)
(4)
(15)
(3)
(3)
(2)
(14)
(2)
(2)
(6)
(15)
(13)
(4)
(2)
(3)
(5)
(2)
(2)
(5)
(8)
(2)
(4)
(2)
(3)
(2)
(3)
(7)
(2)
(2)
(4)
(4)
(2)
(4)
(2)
(2)
(2)
(2)
0 of 1000
(2)
(1)
(113)
(2)
(8)
(1)
(2910)
(5)
(2018)
(13)
(35)
(84)
(3)
(1)
(1)
(2)
(4)
(14)
(1)
(53)
(4075)
(2)
(4)
0 of 23
(1)
(2)
(15)
(33)
(13)
(1)
(8)
(2)
(2)
(4)
(5)
(25)
(1)
(7)
(2)
(180)
(1)
(113)
(2)
(3)
(7)
(1)
(3)
(10)
(11)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(14)
(168)
(159)
(1)
(1)
(1)
(1)
(20)
(1)
(28)
(1)
(2)
(23)
(2)
(1)
(1)
(1)
(1)
(1)
(23)
(8)
(1)
(2)
(3)
(1)
(6)
(1)
(19)
(1)
(7)
(2)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(3)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(12)
(1)
(1)
(1)
(2)
(1)
(16)
(1)
(1)
(3)
(1)
(20)
(1)
(5)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(4)
(1)
(2)
(2)
(2)
(1)
(871)
(2)
(1)
(11)
(1)
(3)
(6)
(1)
(1)
(1)
(87)
(4)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(3)
(2)
(1)
(1)
(14)
(3)
(53)
(1)
(4)
(1)
(1)
(1)
(8)
(17)
(1)
(1)
(1)
(1)
(7)
(1)
(8)
(266)
(1)
(7)
(1)
(1)
(3)
(201)
(2)
(2)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(1)
(2)
(2)
(39)
(1)
(14)
(13)
(1)
(5)
(1)
(2)
(11)
(1)
(1)
(177)
(2)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(4)
(1)
(7)
(1)
(1)
(1)
(4)
(68)
(1)
(1)
(1)
(1)
(1)
(1)
(12)
(39)
(2)
(1)
(1)
(5)
(3)
(12)
(315)
(1)
(1)
(1)
(1)
(28)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(468)
(3)
(6)
(42)
(3)
(12)
(5)
(1)
(4)
(10)
(1)
(1)
(20)
(1)
(8)
(1)
(1)
(1)
(3)
(2)
(15)
(14)
(8)
(2)
(18)
(1)
(112)
(1)
(1)
(1)
(1)
(4)
(5)
(24)
(1)
(1)
(9)
(3)
(76)
(1)
(307)
(1)
(1)
(1)
(31)
(161)
(12)
(1)
(174)
(3)
(3)
(10)
(7)
(25)
(1)
(1)
(1)
(4)
(23)
(42)
(1)
(1)
(1)
(1)
(111)
(1)
(1)
(1)
(1)
(213)
(18)
(1)
(1)
(9)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(7)
(4)
(1)
(1)
(1)
(1)
(4)
(32)
(1)
(1)
(1)
(1)
(2)
(3)
(1)
(13)
(3)
(96)
(1)
(1)
(2)
(4)
(5)
(209)
(1)
(2)
(3)
(1)
(1)
(127)
(9)
(7)
(3)
(2)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(204)
(1)
(1)
(272)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(55)
(1)
(1)
(1)
(1)
(1)
(5)
(265)
(12)
(5)
(3)
(11)
(1)
(8)
(3)
(1)
(1)
(1)
(3)
(1)
(306)
(3)
(1)
(131)
(2)
(1)
(163)
(1)
(1)
(1)
(77)
(4)
(3)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(2)
(1)
(3)
(1)
(2)
(3)
(3)
(112)
(1)
(1)
(9)
(2)
(27)
(34)
(2)
(1)
(1)
(3)
(1)
(18)
(1)
(5)
(3)
(3)
(60)
(1)
(237)
(2)
(1)
(187)
(2)
(1)
(5)
(1)
(500)
(1)
(6)
(2)
(16)
(1)
(7)
(5)
(156)
(1)
(1)
(1)
(6)
(3)
(9)
(4)
(31)
(1)
(1)
(4)
(1)
(248)
(1)
(45)
(1)
(2)
(4)
(10)
(8)
(1)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(558)
(114)
(1)
(1)
(4)
(10)
(1)
(1)
(267)
(1)
(57)
(80)
(241)
(256)
(318)
(52)
(45)
(51)
(88)
(72)
(1)
(1)
(1)
(1)
(1)
(3)
(6)
(8)
(31)
(8)
(7)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(300)
(1)
(1)
(13)
(10)
(2)
(27)
(1)
(1)
(1)
(1)
(1)
(18)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(19)
(1)
(1)
(1)
(5)
(16)
(1)
(2)
(1)
(154)
(1)
(1)
(1)
(5)
(1)
(9)
(1)
(1)
(3)
(2)
(1)
(90)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(5)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(3)
(3)
(1)
(4)
(1)
(4)
(1)
(1)
(1)
(8)
(1)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(18)
(13)
(1)
(14)
(1)
(1)
(13)
(11)
(1)
(2)
(1)
(116)
(46)
(8)
(2)
(1)
(4)
(9)
(4)
(20)
(1)
(2)
(2)
(1)
(5)
(2)
(1)
(2)
(1)
(14)
(1)
(1)
(1)
(1)
(2)
(2)
(22)
(24)
(1)
(1)
(1)
(3)
(1)
(18)
(1)
(1)
(10)
(1)
(1)
(1)
(1)
(1)
(185)
(1)
(1)
(481)
(22)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(11)
(8)
(1)
(1)
(1)
(7)
(1)
(1)
(130)
(1)
(24)
(1)
(1)
(67)
(7022)
(1)
(11)
(1)
(1)
(5)
(11)
(154)
(1)
(1)
(11)
(79)
(1)
(1)
(3)
(31)
(3)
(1)
(4)
(215)
(4)
(2)
(1)
(1)
(30)
(2)
(1)
(390)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(256)
(1)
(1)
(195)
(1)
(1)
(2)
(1)
(45)
(1)
(3)
(9)
(6)
(8)
(9)
(1)
0 of 772
(1)
(55)
(9)
(2)
(2)
(25)
(294)
(2)
(2)
(2)
(3)
(1)
(5)
(27)
(1)
(3)
(5)
(14)
(61)
(10)
(1)
(2)
(5)
(1)
(729)
(2)
(2776)
(5)
(5)
(37)
(1)
(15)
(1)
(7)
(3)
(16)
(27)
(1)
(108)
(2)
(383)
(52)
(1)
(1)
(1)
(1)
(2027)
(1)
(5)
(1)
(8)
(366)
(4)
(3)
(50)
(3)
0 of 56
(3)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(8)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(2)
(3)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(6)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(3)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
0 of 794
(82)
(4)
(1)
(6)
0 of 4
Showing 981 - 1000 of 9537 results
  • Morbidity and Mortality Weekly Report MMWR Surveillance Summaries January 2022 Vol 71 No SS2
    Morbidity and Mortality Weekly Report (MMWR): Surveillance Summaries, January 2022 / Vol. 71 / No. SS-2
    Phares, Christina R. ;
    Liu, Yecai
    01/21/2022 | Surveillance Summaries: Morbidity and Mortality Weekly Report (MMWR)
    Each year, approximately 500,000 immigrants and tens of thousands of refugees (range: 12,000–85,000 during 2001–2020) move to the U.S. While still abroad, immigrants, refugees, and others who apply for admission to live permanently in the U.S. must undergo a medical examination. This examination identifies persons with class A or B conditions. Appl ...
    Supporting Files Public Domain
  • Effectiveness of a Third Dose of mRNA Vaccines Against COVID19Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION Network 10 States August 2021January 2022
    Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
    Thompson, Mark G. ;
    Natarajan, Karthik
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination of these and other factors. CDC recommends that all persons aged ≥12 years receive a third dose (booster) of an mRNA vaccine ...
    Supporting Files Public Domain
  • QuickStats Percentage of Children Aged 217 Years with 2 Hours of Screen Time Per Weekday by Sex and Age Group National Health Interview Survey US 2020
    QuickStats: Percentage of Children Aged 2–17 Years with >2 Hours of Screen Time Per Weekday, by Sex and Age Group — National Health Interview Survey, U.S. 2020
    Ng, Amanda E. ;
    Black, Lindsey I.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Overall, 65.7% of boys and 64.6% of girls aged 2–17 years spent >2 hours of screen time per weekday, in addition to screen time spent for schoolwork. Among both boys and girls, the percentage of children who spent >2 hours of screen time increased with increasing age group from 47.5% for those aged 2–5 years to 80.2% for those aged 12–17 years.Sour ...
    Supporting Files Public Domain
  • Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged 19 Years Recommendations of the Advisory Committee on Immunization Practices US 2022
    Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — U.S. 2022
    Anderson, Tara C. ;
    Masters, Nina B.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit vaccine containing recombinant glycoprotein E in combination with adjuvant (AS01|) that was licensed in the U.S. for Prevention of herpes zoster for adults aged ≥50 years by the Food and Drug Administration (FDA) and recommended for immunocomp ...
    Supporting Files Public Domain
  • Use of the Janssen Johnson Johnson COVID19 Vaccine Updated Interim Recommendations from the Advisory Committee on Immunization Practices United States December 2021
    Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
    Oliver, Sara E. ;
    Wallace, Megan
    01/21/2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for its ...
    Supporting Files Public Domain
  • Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID19 US March 2020August 2021
    Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — U.S. March 2020–August 2021
    Wiltz, Jennifer L. ;
    Feehan, Amy K.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The COVID-19 pandemic has magnified longstanding health care and social inequities, resulting in disproportionately high COVID-19-associated illness and death among members of racial and ethnic minority groups (1). Equitable use of effective medications (2) could reduce disparities in these severe outcomes (3). Monoclonal antibody (mAb) therapies a ...
    Supporting Files Public Domain
  • Effectiveness of a Third Dose of MRNA Vaccines Against COVID19associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance VISION Network 10 States August 2021January 2022
    Effectiveness of a Third Dose of MRNA Vaccines Against COVID-19–associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variants Predominance — VISION Network, 10 States, August 2021–January 2022
    Thompson, Mark G. ;
    Natarajan, Karthik
    January 21, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? COVID-19 mRNA vaccine effectiveness (VE) in preventing COVID-19 might decline because of waning of vaccine-induced immunity or Variants immune evasion.What is added by this report? VE was significantly higher among patients who received their second mRNA COVID-19 vaccine dose <180 days before medical encounters compared with those vaccinated ≥180 days earlier. During both Delta- and Omicron-predominant periods, receipt of a third vaccine dose was highly effective at preventing COVID-19–associated emergency department and urgent care encounters (94% and 82%, respectively) and preventing COVID-19–associated hospitalizations (94% and 90%, respectively).What are the implications for public health practice? All unvaccinated persons should start vaccination as soon as possible. All adults who have received mRNA vaccines during their primary COVID-19 vaccination series should receive a third dose when eligible, and eligible persons should stay up to date with COVID-19 vaccinations.Suggested citation for this article: Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. ePub: 21 January 2022.mm7104e3.htm?s_cid=mm7104e3_wmm7104e3-H.pdf
    Supporting Files Public Domain
  • Notes From the Field Early Evidence of the SARSCoV2 B11529 Omicron Variants in Community Wastewater United States NovemberDecember 2021
    Notes From the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variants in Community Wastewater — United States, November–December 2021
    Kirby, Amy E. ;
    Welsh, Rory M.
    1 21 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    No Description
    Supporting Files Public Domain
  • COVID19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variants Emergence 25 US Jurisdictions April 4December 25 2021
    COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variants Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021
    Johnson, Amelia G. ;
    Amin, Avnika B.
    January 21, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? Although COVID-19 vaccine effectiveness decreased with emergence of the Delta Variants and waning of vaccine-induced immunity, protection against hospitalization and death has remained high.What is added by this report? In 25 U.S. jurisdictions, decreases in case incidence rate ratios for unvaccinated versus ...
    Supporting Files Public Domain
  • Incidence of COVID19 Cases and Deaths Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence 25 US jurisdictions April 4December 25 2021
    Incidence of COVID-19 Cases and Deaths Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. jurisdictions, April 4–December 25, 2021
    Centers for Disease Control and Prevention (U.S.)
    01/21/2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    No Description
    Public Domain
  • COVID19 Cases and Hospitalizations by COVID19 Vaccination Status and Previous COVID19 Diagnosis California and New York MayNovember 2021
    COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021
    León, Tomás M. ;
    Dorabawila, Vajeera
    January 19, 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? Data are limited regarding the risks for SARS-CoV-2 infection and hospitalization after COVID-19 vaccination and previous infection.What is added by this report? During May–November 2021, case and hospitalization rates were highest among persons who were unvaccinated without a previous Diagnosis. Before Delta ...
    Supporting Files Public Domain
  • COVID19 Cases and Hospitalizations by COVID19 Vaccination Status and Previous COVID19 Diagnosis California and New York MayNovember 2021
    COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021
    Centers for Disease Control and Prevention (U.S.)
    01/18/2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    No Description
    Public Domain
  • Trends in Breast Cancer Incidence by Race Ethnicity and Age Among Women Aged 20 Years US 19992018
    Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥20 Years — U.S. 1999–2018
    Ellington, Taylor D. ;
    Miller, Jacqueline W.
    1 14 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Breast cancer is commonly diagnosed among women, accounting for approximately 30% of all cancer cases reported among women.* A slight annual increase in breast cancer incidence occurred in the U.S. during 2013-2017 (1). To examine Trends in breast cancer incidence among women aged ≥20 years by race/ethnicity and age, CDC analyzed data from U.S. Can ...
    Supporting Files Public Domain
  • Impact of the DREAMS Program on New HIV Diagnoses in Adolescent Girls and Young Women Attending Antenatal Care Lesotho 20152020
    Impact of the DREAMS Program on New HIV Diagnoses in Adolescent Girls and Young Women Attending Antenatal Care — Lesotho, 2015–2020
    Pelletier, Andrew R. ;
    Derado, Josip
    1 14 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Lesotho is a small, landlocked country in southern Africa with a population of approximately 2 million persons, approximately two thirds of whom live in rural areas (1). Lesotho has the second highest prevalence of HIV infection in the world (2). In 2017, 25.6% of persons aged 15-59 years living in Lesotho were HIV-positive (3). Strategies implemen ...
    Supporting Files Public Domain
  • QuickStats Percentage of Adults Aged 18 Years Who Received Care At Home From a Friend Or Family Member in the Past 12 Months by Sex and Age Group National Health Interview Survey US JulyDecember 2020
    QuickStats: Percentage of Adults Aged ≥18 Years Who Received Care At Home From a Friend Or Family Member in the Past 12 Months, by Sex and Age Group — National Health Interview Survey, U.S. July–December 2020
    Ng, Amanda E. ;
    Vahratian, Anjel
    1 14 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    During July–December 2020, 10.0% of adults aged ≥18 years received care at home from a friend or family member in the past 12 months. Among both men and women, the percentage of adults who received care in the past 12 months increased with age. Women were more likely than men to receive care among those aged ≥18 years (11.5% and 8.5%, respectively) ...
    Supporting Files Public Domain
  • Effectiveness of BNT162b2 PfizerBioNTech mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 1218 Years US JulyDecember 2021
    Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — U.S. July–December 2021
    Zambrano, Laura D. ;
    Newhams, Margaret M.
    1 14 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the Virus that causes COVID-19 (1-3). In the U.S. the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children ...
    Supporting Files Public Domain
  • Morbidity and Mortality Weekly Report Supplement January 14 2022 Vol 71 No1
    Morbidity and Mortality Weekly Report: Supplement, January 14, 2022 / Vol. 71 / No.1
    Carande-Kulis, Vilma ;
    Elder, Randy W.
    January 14, 2022 | Supplements: Morbidity and Mortality Weekly Report (MMWR)
    CDC is the nation's premier health promotion, Prevention, and preparedness agency. As such, CDC is an important source of public health and clinical guidelines. If CDC guidelines are to be trusted by partners and the public, they must be clear, valid, and reliable. Methods and processes used in CDC guideline development should follow universally ac ...
    Supporting Files Public Domain
  • Risk for Newly Diagnosed Diabetes 30 Days After SARSCoV2 Infection Among Persons Aged 18 Years US March 1 2020June 28 2021
    Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — U.S. March 1, 2020–June 28, 2021
    Barrett, Catherine E. ;
    Koyama, Alain K.
    1 14 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The COVID-19 pandemic has disproportionately affected people with diabetes, who are at increased risk of severe COVID-19.* Increases in the number of type 1 diabetes diagnoses (1,2) and increased frequency and severity of diabetic ketoacidosis (DKA) at the time of diabetes Diagnosis (3) have been reported in European pediatric populations during th ...
    Supporting Files Public Domain
  • Evaluation of StateLed Surveillance of Neonatal Abstinence Syndrome Six US States 20182021
    Evaluation of State-Led Surveillance of Neonatal Abstinence Syndrome — Six U.S. States, 2018–2021
    Jilani, Shahla M. ;
    West, Kristina
    1 14 2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Opioid use disorder (OUD) is a significant public health problem in the U.S. which affects children as well as adults. During 2010-2017, maternal opioid-related diagnoses increased approximately 130%, from 3.5 to 8.2 per 1,000 hospital deliveries, and neonatal abstinence syndrome (NAS) increased 83%, from 4.0 to 7.3 per 1,000 hospital deliveries (1 ...
    Supporting Files Public Domain
  • Supplementary table and Supplementary figure for Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID19 US March 2020August 2021
    Supplementary table and Supplementary figure for: Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — U.S. March 2020–August 2021
    Centers for Disease Control and Prevention (U.S.)
    01/14/2022 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    Suppl.ementary table and Suppl.ementary figure for: Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — U.S. March 2020–August 2021. MMWR Morb Mortal Wkly Rep 2022;71:96–102.
    Public Domain
981 - 1000 / 9537
 Was this page helpful?
 Found an issue?
Send us an email at: publishinghd@cdc.gov